Searched for
CIPHER PHARMACEUTICALS
Reduce Sun Pharma, target Rs 447: Prabhudas LilladherReduce Sun Pharmaceutical Industries Ltd. at a price target of Rs 447.- Cipher, Ranbaxy settle patent litigation with ActavisCipher Pharma Inc, along with partners Ranbaxy - a Sun Pharma firm - and Galephar Pharmaceutical Research, has entered into a patent litiga...
- Ranbaxy launches acne treatment capsules in the US marketRanbaxy Laboratories Inc has announced the launch of Absorica capsules in the strengths of 25 mg and 35 mg in the US market.
- Ranbaxy inks pact with Cipher to sell acne drug in BrazilRanbaxy has inked a licensing pact with Cipher Pharmaceuticals Inc to exclusively market its isotretinoin capsules, used to treat acne, in ...
- Watson Laboratories send patent challenge notice to Ranbaxy for acne drugRanbaxy Laboratories' US arm has received a notice from Watson Laboratories, challenging the patent of acne treatment drug Absorica.
- Ranbaxy launches anti-acne drug in the US marketAccording to an analyst, the launch of Absorica would greatly benefit Ranbaxy as there are only 2-3 players currently selling the product i...
- Ranbaxy to relaunch bessling brandRanbaxy Laboratories has received US drug regulator's approval to relaunch one of its best selling brand in the US after being banned for n...
- Ranbaxy plans to re-launch skincare brand Sotret in USThe US drug regulator will have a final review of the drug on May 29, it said.Cipher specialises in developing improved formulations of exi...
Load More